Platinum-based chemotherapy was recommended as first-line chemotherapy regimen for advanced NSCLC in National Comprehensive Cancer Network (NCCN) guideline, especially, those without epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangement and proto-oncogene tyrosine-protein kinase ROS (ROS1) translocations [4]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.